Research Studies funded by:
National Institutes of Health (NIH)
Type 1 diabetes (NIDDK)
1983 – Present
Diabetes Control and Complications Trials (DCCT) and the follow-up study Epidemiology of Diabetes Interventions and Complications (EDIC). Improved glucose control prevents or delays complications in T1D. The research finding of metabolic memory shows that early improved glycemic control is important in preventing future complications.
Type 2 diabetes (NHLBI)
Action to Control Cardiovascular Risk in Diabetes (ACCORD) and the follow-up study ACCORD.
Multi-center randomized trial evaluating if near normal glycemic control can prevent cardiovascular disease in type 2 diabetes.
New Technology to Manage Insulin Therapy (NIDDK)
Small Business (STTR) grant a partnership between Hygieia Medical & IDC.
Frequent adjustment of insulin by following suggested insulin doses from an automated device improves glucose control and reduces hypoglycemia.
Helmsley Trust Foundation Funding
Type 1 Diabetes Exchange Network and Standard Glucose Monitor Display and Analysis
A research grant to establish a registry of patients with type 1 diabetes in 66 clinics across the United States for research purposes and to improve clinical care.
A research grant to determine and test the best approach to displaying and analyzing glucose data in order to improve quality of life and clinical outcomes.
Clinical Trials Testing New Medications to improve diabetes care
Testing new ultra-rapid and ultra-long acting insulins.
Testing new incretin type medications – GLP-1 Agonists, DPP4-I.
Testing insulin use at the onset of T2D to see if it prevents CVD – Origin Trial.
Testing the cardiovascular safety of diabetes medications.
Clinical Trials Testing New Technology to improve diabetes care
Testing the combined use of insulin pumps and continuous glucose monitors - STAR 3 trial.
Testing the value of self monitored blood glucose (SMBG) data to improve glucose control.
Testing the value of continuous glucose monitoring (CGM) data to improve glucose control.
Comparing the value of A1C, SMBG or CGM to improve glucose control.
Dr. Bergenstal has published more than 150 peer-reviewed scientific articles in diabetes. In 2010, he was the lead author for articles published in the New England Journal of Medicine and the Lancet.
Bergenstal RM, Tamborlane WV, Ahmann A, Buse JB, Dailey G, Davis SN, Joyce C, Peoples T, Perkins BA, Welsh JB, Willi SM and Wood MA for the STAR 3 Study Group: Effectiveness of sensor-augmented insulin--pump therapy in type 1 diabetes. NEJM 363(4):311-320, July 22, 2010.
Bergenstal RM, Wysham C, MacConnell L, Malloy J, Walsh B, Yan P, Wilhelm K, Malone J and Porter LE for the DURATION-2 Study Group: Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. The Lancet 376(9739):431-439, August 7, 2010.
Bergenstal RM, Garrison LP Jr, Wintle M, Blickensderfer A, Wade R, Hou L, Miller LA, Scism-Bacon J, Zagar A, Misurski D, Herman WH. Exenatide bid observational study (ExOS): baseline population characteristics of a prospective research study to evaluate the clinical effectiveness of exenatide bid use in patients with type 2 diabetes in a real-world setting. Current Medical Research and Opinion. March 2011. 27(3):531-40.
Bergenstal RM, Tamborlane WV, Ahmann A, Buse JB, Dailey G, Davis SN, Joyce C, Perkins BA, Welsh JB, Willi SM, Wood MA; for the STAR 3 Study Group. Sensor-augmented pump therapy for A1C reduction (STAR 3) study: Results from the 6-month continuation phase. Diabetes Care. September 2011. (Epub).